French vaccine manufacturer Sanofi, which acquired India's Shantha Biotechnics in 2009, will set up an insulin production facility in Telangana, India, involving an investment of Rs 460 crore (roughly $100M USD).
Sanofi will use the facility to manufacture Insuman, one of its leading human insulin product for diabetes treatment. The site will have a capacity to produce 60 million cartridges a year.
The new facility, spread over 13,400 sq. m, will be fully operational by 2019, according to the company. The facility will be Sanofi’s second largest Insuman factory, which the largest one in Frankfurt, Germany.
Read the ET press release